CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

• Optimized Urine Liquid Biopsy Workflow

  Urine-derived cell-free DNA is revolutionizing liquid biopsy research to offer a non-invasive, accessible tool for early disease detection, monitoring, and comprehensive diagnostics across oncology.

• Smart Scaling For Cell And Gene Therapies

  To meet patient demand, advanced therapy manufacturing processes must be commercial ready. CGT sponsors can mitigate risk and protect viability by partnering with a CDMO that prioritizes scalability.

• Controlling mAb Aggregates In Chromatography Process Development

  Antibody aggregation remains a critical downstream challenge, particularly for complex modalities. Explore why aggregates form, why they matter, and how chromatographic strategies can help reduce risk.

• Automated Library Prep For A Nanopore DNA Barcoding Protocol

  A streamlined workflow reduces reagent use and hands‑on time while preserving long‑read sequencing quality. See how multiplexed offer an efficient option for scaling or mobilizing sequencing efforts.

• Navigating Patient Access Challenges In Commercializing Your CGT Product

  Learn how to effectively break down barriers to patient access in cell and gene therapy by enhancing provider education, streamlining coordination, and expanding patient support.

• Developing Consistent And Reproducible 3D Spheroid Models

  Improve 3D spheroid consistency by optimizing cell selection, seeding density, and plate geometry. See how practical workflows and comparative data help reduce variability and establish reliability.

• Quantification Of Total mRNA Content In LNP Complexes

  Learn how rapid, non-destructive techniques for mRNA quantification in LNPs can improve dosing accuracy, reduce variability, and accelerate decision-making for efficient scale-up and commercialization.

• The Key To Viral Vector Success

  Establishing a robust and scalable viral vector process requires a multidisciplinary approach that incorporates expertise in foundational science, analytics, and biomanufacturing.

• A Clear Path To Rapid, Consistent Biosimilar Development

  Faster timelines don’t have to come at the expense of quality or consistency. Discover proven strategies to generate stable, high-performing cell lines while reducing risk and supporting reliable scale-up.

• Best Practices For Oncolytic Virus Design, Development, Manufacturing

  Oncolytic viruses have the potential to revolutionize standard cancer treatment, but their continued progress hinges on meeting a number of goals linked to safety, efficacy, and commercial scale-up.